

### **GSK Africa Strategy**




VISION: Build an integrated and local African healthcare company with the capabilities, people, and portfolio to reach patients in Sub-Saharan Africa



## Africa NCD Open Lab – concept overview







**Progress to date** 

### **External Scientific Advisory Board**





Moffat Nyirenda Malawi



Dwomoa Adu Ghana



Corey Casper USA



Tumani Corrah The Gambia



Julie Makani Tanzania



Bongani Mayosi South Africa



Jean Claude Mbanya Cameroon



Nicola Mulder South Africa



Nelson Sewankambo Uganda



Gerald Yonga Kenya



Heather Zar South Africa

## **Call for proposals – kick-starting research efforts**



#### **GSK call**

- 8 SSA countries in scope
- Up to £4m available together with potential access to GSK expertise
- Call closed Jan 2015
- Proposals now under review
- Aim to start first projects 2H2015




### GSK, MRC South Africa, MRC UK call

- Focus is on South Africa
- Up to £5m available (£4m from external partners) together with potential access to GSK expertise
- Proposals must have relevance to wider SSA
- Call closes 28 June 2015

# **Africa NCD Open Lab – Training, Centres**





### **H3Africa - Possible Areas for Collaboration**



Translating H3Africa research findings into potential therapeutics



- Pharmacogenomics (PGx) opportunities:
  - ADME genetic variation
  - ADME activity variation
  - PGx insights in existing H3A projects
- GSK PGx contributions:
  - Design, analysis and interpretation of PGx data
  - Drug metabolism and drug transporter expertise

